Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stock Report

Market Cap: US$37.4k

Acorda Therapeutics Balance Sheet Health

Financial Health criteria checks 0/6

Acorda Therapeutics has a total shareholder equity of $-185.8M and total debt of $191.5M, which brings its debt-to-equity ratio to -103.1%. Its total assets and total liabilities are $81.6M and $267.3M respectively.

Key information

-103.1%

Debt to equity ratio

US$191.47m

Debt

Interest coverage ration/a
CashUS$9.36m
Equity-US$185.77m
Total liabilitiesUS$267.35m
Total assetsUS$81.58m

Recent financial health updates

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05
Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

Acorda inks license deal with Asieris for pre-clinical drug

Aug 29

Acorda Therapeutics announces resignation of COO

Aug 19

Acorda Therapeutics: Managing The Transition

Oct 04

Acorda Therapeutics Continues To Maneuver For A Turnaround

Jul 24

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Financial Position Analysis

Short Term Liabilities: ACOR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ACOR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ACOR.Q has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ACOR.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACOR.Q has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACOR.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.5% each year


Discover healthy companies